Poxel was able to score positive results for its type 2 diabetes drug in a Phase IIb study in Japan, preparing the company to go for a Phase III program. Poxel, one of
Medical Research
This growth is across the nine major countries of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China The human immunodeficiency virus (HIV) market is set to
A plastic bag-like medical device filled with amniotic fluid acting as an ‘artificial womb’ has been tested successfully in a study using unborn lambs. The womb-like environment designed by paediatric
Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials. The
Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from
Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell
Allergan, a global biopharmaceutical company, announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR
Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial
Two startups in the fields of synthetic biology, Biosyntia and FGen, have struck a partnership to identify promising microbial strains. The objective is to find a strain that enables bioproduction
Allergan plc, a global pharmaceutical company announced topline data from a phase II study with major depressive disorder (MDD). The study evaluated the efficacy, safety and tolerability of a single administration
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy. One
Scientists from LSTM’s Research Centre for Drugs and Diagnostics (RCDD) have described in a paper published today in Scientific Reports, a new way of screening potential treatments for Tuberculosis (TB)
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections. Antimicrobial resistance is one of the greatest
Zika virus (ZIKV), which causes Zika virus disease, is spread to people primarily through the bite of an infected Aedes aegypti or Aedes albopictus mosquito. An infected pregnant woman can pass ZIKV to her
Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches
PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio
A new study published in PLOS Medicine’s Special Issue on Dementia has found that the metabolism of omega-3 and omega-6 unsaturated fatty acids in the brain are associated with
Medical device firm Mainstay Medical said operating expenses rose by $3.9 million for 2016 to $16.8 million as Mainstay kicked off its ReActiv-8 B clinical trial and began commercialising the
Researchers at Trinity College Dublin have discovered a way to prevent bacteria from growing on medical devices that are implanted in the human body. The researchers state the discovery is
Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World Parkinson’s Day on
Shire has secured label expansion approval from the European Commission for its hereditary angioedema therapy Cinryze. The European Commission (EC) has approved the label extension application, granting three new indications
Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The
Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received
Novartis has received FDA approval for Kisqali, a first-line treatment for breast cancer originally developed by the British biotech Astex
Scientists from the University of Cambridge have determined the first 3D structures of mammalian genomes from individual cells. For the
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced
Cambridge Academy of Therapeutic Sciences aims to create world-leading industry-academia collaborations with new initiative The Cambridge Academy of Therapeutic Sciences
The Museum of the History of Science in Oxford is hosting an exhibition on the history of penicillin and the
A medical team from Clínica Universidad de Navarra in Pamplona has successfully performed Spain’s first implant of the SynCardia temporary
SenzaGen and AstraZeneca will develop a new genomic signature to distinguish allergens from irritants in the respiratory tract Swedish in
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the
Score one for Samsung Bioepis in its quest to bring a biosimilar version of AbbVie’s anti-inflammatory behemoth Humira to market in
Medical device company Olberon has developed a product to help doctors and nurses insert needles into patients’ blood. Olberon states
Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor
Actelion has received approval from the European Commission for Ledaga, a treatment to prevent the progression of a rare form
A new method to help diagnose oesophageal cancer is being researched by engineers and physicians at the Institute of Biological
Diagnostics company, Owlstone Medical, who is developing a breathalyser for disease has announced it has signed a master service agreement
Researchers at the Universities of Dundee and Edinburgh in Scotland are looking to work with the pharmaceutical industry to improve
Sanofi and its vaccines global business unit Sanofi Pasteur announced today an agreement with MedImmune, the global biologics research and development arm of
In September 2015, the German Volkswagen Group, the world’s largest car producer, admitted to having installed “defeat devices” in 11
A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough
On 1 March the newly established European Reference Networks (ERNs) has started their work. ERNs are unique and innovative cross-border
29 – 31 March 2017, Glasgow, United Kingdom. DIA, (founded as the Drug Information Association) announced critical workshops to be
Early-phase contract research organisation Richmond Pharmacology has opened its new research facility in London Bridge, at the site formerly known
The World Health Organization has issued a list of the top dozen bacteria most dangerous to humans, warning that doctors
The joint venture will combine Sanofi’s biologics development pipeline with Lonza’s expertise to design, construct, start-up and operate a state-of-the-art
FDA’s Office of Generic Drugs (OGD) released their 2016 Annual Report on Feb. 24, 2017. The report details the office’s accomplishments
The European Medicines Agency (EMA) announced on Feb. 24, 2017 that its Committee for Medicinal Products for Human Use (CHMP) has
GlaxoSmithKline plc and Innoviva, Inc. announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were
Advertisements
